Vito Palombella - Infinity Pharmaceuticals Chief Scientific Officer and Executive VP
| INFIDelisted Stock | USD 0.04 0.03 42.86% |
EVP
Dr. Vito J. Palombella Ph.D. is no longer Chief Scientific Officer of Infinity Pharmaceuticals Inc effective January 22 2016. He is responsible for our drug discovery and preclinical development activities. Prior to his role as Chief Scientific Officer Dr. Palombella was Vice President Drug Discovery from September 2006 to May 2010 and Vice President Biology of IPI from January 2004 to September 2006. Prior to joining Infinity Dr. Palombella was Director of Molecular Biology and Protein Chemistry at Syntonix Pharmaceuticals where he was responsible for improving and expanding its core Fc receptormediated drug delivery technology. Before joining Syntonix Dr. Palombella was Senior Director of Cell and Molecular Biology at Millennium Pharmaceuticals which he joined through its acquisition of LeukoSite at which he held the same title in 1999. Prior to its acquisition by LeukoSite Dr. Palombella held a number of positions at ProScript Inc. between 1994 and 1999. While at ProScript LeukoSite and Millennium Dr. Palombella was involved in the discovery and development of bortezomib also known as Velcade a proteasome inhibitor for cancer therapy. He also managed a number of additional projects including research into NFkB regulation since 2010.
| Age | 51 |
| Tenure | 14 years |
| Phone | 617 453 1000 |
| Web | https://www.infi.com |
Infinity Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.607) % which means that it has lost $0.607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.2135) %, meaning that it created substantial loss on money invested by shareholders. Infinity Pharmaceuticals' management efficiency ratios could be used to measure how well Infinity Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 917 K in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Infinity Pharmaceuticals has a current ratio of 4.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Infinity Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Infinity Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Infinity Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Infinity to invest in growth at high rates of return. When we think about Infinity Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuti operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. Infinity Pharmaceuticals (INFI) is traded on NASDAQ Exchange in USA and employs 30 people. Management Performance
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 |
Infinity Pharmaceuticals Leadership Team
Elected by the shareholders, the Infinity Pharmaceuticals' board of directors comprises two types of representatives: Infinity Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Infinity. The board's role is to monitor Infinity Pharmaceuticals' management team and ensure that shareholders' interests are well served. Infinity Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Infinity Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Pearlberg, Vice President - Clinical Development | ||
| Melissa Hackel, Vice President - Finance | ||
| William Bertrand, Executive Vice President General Counsel | ||
| Vito Palombella, Chief Scientific Officer and Executive VP | ||
| Jeffrey Berkowitz, Independent Director | ||
| Seth JD, Chief VP | ||
| Lawrence Bloch, CFO, Executive Vice President Chief Business Officer | ||
| Norman Selby, Lead Outside Independent Director | ||
| Jose Baselga, Independent Director | ||
| Samuel Agresta, Chief Medical Officer | ||
| Michael Venuti, Independent Director | ||
| Stephane Peluso, Chief Officer | ||
| MD Ilaria, Chief Officer | ||
| Jayne Kauffman, Sr Coordinator | ||
| Michael Kauffman, Independent Director | ||
| Eric Lander, Independent Director | ||
| David Beier, Independent Director | ||
| Julian Adams, President of RandD | ||
| Anthony Evnin, Independent Director | ||
| Gwendolyn Fyfe, Independent Director | ||
| Sujay Kango, Executive Vice President Chief Commercial Officer | ||
| Ian Smith, Independent Director | ||
| Adelene Perkins, Chairman of The Board, CEO and Pres | ||
| MD JD, Pres Treasurer |
Infinity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Infinity Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (15.70) % | |||
| Current Valuation | (9.46 M) | |||
| Shares Outstanding | 90.76 M | |||
| Shares Owned By Insiders | 2.36 % | |||
| Shares Owned By Institutions | 23.48 % | |||
| Number Of Shares Shorted | 2.21 M | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 8.03 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Infinity Pharmaceuticals information on this page should be used as a complementary analysis to other Infinity Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |